Delivery Order SPE2DB20D3104-SPE2DB24FV9B7

Award Date 8/28/24
Potential Completion Date 8/29/24
Potential Value $1.2K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a Delivery Order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $2,532.06, is for the delivery of 4567694566 ATOMOXETINE HCL 25 MG CAPSULE 30S. The contract has a firm fixed price and an ultimate completion date of March 26, 2025. The contract is not designated as a set-aside. AmerisourceBergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distribution and healthcare solutions provider. The contract, valued at $1,086.12, is for the delivery of ATOMOXETINE HCL 40 MG CAPSULE 30S, a specialty medication. The contract has a firm fixed price pricing type and a completion date of January 9, 2025. This delivery order is part of a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 held by...
This firm fixed price delivery order was awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, a leading global pharmaceutical sourcing and distribution services company. The $1,723.67 award is for the delivery of ATOMOXETINE HCL 40 MG CAPSULE 30S, a pharmaceutical product, with a completion date of February 12, 2024. The contract does not have a set-aside designation. Amerisourcebergen Drug Corp holds an Indefinite...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the supply of 4564460088 - ATOMOXETINE HCL 40 MG CAPSULE 30S, a specialty medication, with a ceiling value of $1,624.36 and a performance period through May 2, 2024. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a subsidiary of the parent company Cencora, Inc. The contract, valued at $2,124.78, is for the delivery of 4564478665 - ATOMOXETINE HCL 25 MG CAPSULE 30S. The contract has a firm fixed price pricing type and an ultimate completion date of May 3, 2024. The contract was awarded on May 2, 2024 and does not have a set-aside designation, indicating it was awarded...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $1,228.10, is for the delivery of Atomoxetine HCl 40 mg capsules. The contract is a firm fixed-price agreement with a period of performance through November 1, 2024. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at...
This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $2,727.36, is for the delivery of ATOMOXETINE HCL 40 MG CAPSULE 30S, a prescription medication. The contract is a Delivery Order with a Firm Fixed Price pricing type and has an Ultimate Completion Date of December 20, 2024. This contract award is part of a larger Indefinite Delivery Contract (IDC)...
This is a federal contract awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $1,000.45, is a Delivery Order for the supply of 4562879322 ! ATOMOXETINE HCL 60 MG CAPSULE 30S. The contract has a period of performance through November 22, 2023 and is a Firm Fixed Price arrangement. Amerisourcebergen Drug Corp is a for-profit corporate entity that specializes in distributing a...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of Atomoxetine HCL 40 mg capsules. The firm-fixed-price contract, which does not have a set-aside designation, has a ceiling value of $1,891.58 and an ultimate completion date of September 30, 2024. AmerisourceBergen, through its Corporate Office Division, is a key contractor for providing a wide range of prescription medications,...
This federal contract award is a delivery order (SPE2DB20D3104|SPE2DB24FV6Q3) worth $1,809.62, issued by the Defense Logistics Agency (DLA) to the prime contractor Amerisourcebergen Drug Corp. The contract is for the delivery of 4564437085 ATOMOXETINE HCL 40 MG CAPSULE 30S. This order is part of a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 that Amerisourcebergen holds with the DLA Troop Support Medical, which provides a comprehensive range of pharmaceutical products and...
  • SPE2DB20D3104
    Indefinite Delivery Contract
  • SPE2DB20D3104-SPE2DB24FV9B7
    Delivery Order

This is a delivery order (SPE2DB20D3104|SPE2DB24FV9B7) awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp's Corporate Office Division. The contract, valued at $1,241.49, is for the delivery of ATOMOXETINE HCL 60 MG CAPSULE 30S, a pharmaceutical product. The delivery order is part of a larger Indefinite Delivery Contract (IDC) valued at up to $999,999,999 with the DLA Troop Support Medical, which serves as a primary vehicle for AmerisourceBergen to provide a comprehensive range of medical commodities to support military treatment programs and facilities worldwide. The contract has no set-aside designation and is scheduled for completion on August 29, 2024.

Generated 11/27/24, 9:13 AM